Ibrutinib (Imbruvica®) for CLL
Ibrutinib is indicated for the treatment of patients with chronic lymphocytic leukaemia who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p) or TP53 mutation in patients not suitable for chemoimmunotherapy.
Rapid Review
Commenced | Completed | Outcome |
07/11/2014 | 18/12/2014 | Full Pharmacoeconomic Evaluation Recommended. |
Pharmacoeconomic Evaluation
Commenced | Completed | Outcome |
02/04/2015 | 01/10/2015 | Reimbursement Not recommended |
The cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with CLL who have received ≥1 prior therapy, or as a first-line treatment in the presence of del(17p)/TP53 mutation in patients not suitable for chemo-immunotherapy, has not been demonstrated and therefore it is not recommended for reimbursement at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.